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Abstract
Background: The diagnosis of human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense relies mainly
on the Card Agglutination Test for Trypanosomiasis (CATT). There is no immunodiagnostic for HAT caused by T. b.
rhodesiense. Our principle aim was to develop a prototype lateral flow test that might be an improvement on CATT.
Methodology/Principle Findings: Pools of infection and control sera were screened against four different soluble form
variant surface glycoproteins (sVSGs) by ELISA and one, sVSG117, showed particularly strong immunoreactivity to pooled
infection sera. Using individual sera, sVSG117 was shown to be able to discriminate between T. b. gambiense infection and
control sera by both ELISA and lateral flow test. The sVSG117 antigen was subsequently used with a previously described
recombinant diagnostic antigen, rISG65, to create a dual-antigen lateral flow test prototype. The latter was used blind in a
virtual field trial of 431 randomized infection and control sera from the WHO HAT Specimen Biobank.
Conclusion/Significance: In the virtual field trial, using two positive antigen bands as the criterion for infection, the
sVSG117 and rISG65 dual-antigen lateral flow test prototype showed a sensitivity of 97.3% (95% CI: 93.3 to 99.2) and a
specificity of 83.3% (95% CI: 76.4 to 88.9) for the detection of T. b. gambiense infections. The device was not as good for
detecting T. b. rhodesiense infections using two positive antigen bands as the criterion for infection, with a sensitivity of
58.9% (95% CI: 44.9 to 71.9) and specificity of 97.3% (95% CI: 90.7 to 99.7). However, using one or both positive antigen
band(s) as the criterion for T. b. rhodesiense infection improved the sensitivity to 83.9% (95% CI: 71.7 to 92.4) with a
specificity of 85.3% (95% CI: 75.3 to 92.4). These results encourage further development of the dual-antigen device for
clinical use.
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Introduction
Human African Trypanosomiasis (HAT), or African Sleeping
Sickness, is caused by two sub-species of Trypanosoma brucei. T. b.
gambiense accounts for approximately 95% of HAT infections and
occurs across East and Central sub-Saharan Africa. The remain-
ing infections are caused by T. b. rhodesiense in West and Southern
Africa. The disease has two stages: Stage 1, where the parasites are
limited to the bloodstream, interstitial fluids and lymph of the
patient, and stage 2, where parasites are also found in the central
nervous system.
In recent years, the official number of recorded HAT cases has
fallen below 10,000 per year, although possible under-reporting
suggests that this is likely a minimum figure [1–3]. Nevertheless,
with new therapeutic regimes [4–6] and with a repurposed drug
(fexinidazole) [7] and a new chemical entity (an oxaborole) [8] in
clinical trials, the potential to eliminate HAT from many regions
of sub-Saharan Africa at last exists. However, disease elimination
requires excellent and convenient field diagnostics. Currently, the
diagnosis of infected individuals relies principally on screening
teams that visit at-risk communities and from patients seeking
medical help [9,10]. Some patients with T. b gambiense infections
remain asymptomatic for years, so early diagnosis of infected
individuals benefits not only the patient but also the community
where these individuals can act as parasite reservoirs [11]. The
most widely used diagnostic for suspected T. b. gambiense infections
is the Card Agglutination Test for Trypanosomiasis (CATT). This
serological test detects host antibodies to a suspension of fixed and
stained T. b. gambiense trypanosomes expressing variant surface
glycoprotein (VSG) variant LiTaT1.3 [12]. Over the years, the
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CATT screening tool has been optimised to improve stability,
sensitivity (ranging from 87% to 98%) and specificity, (95%) and
thermostability [1,13–16]. A positive CATT is followed up by
microscopic examination of blood buffy coat smears. Until
recently, stage 1 and stage 2 treatment regimes were different,
and the latter much more toxic, such that positive diagnosis of
infection was then staged by microscopic examination of Cerebral
Spinal Fluid (CSF) for the presence of trypanosomes and/or
lymphocytes. However, the use of nifurtimox and eflornithine
combination therapy (NECT) [4–6] in recent years has largely
removed the need for staging diagnosis in T. b gambiese infections.
Despite its usefulness, the CATT screening tool has several
widely acknowledged limitations [17–20]. It requires cultivation of
infectious parasites for its manufacture, trained personnel for use
and the read out is subjective, causing variability in reported
sensitivity and specificity [16,21]. Significantly, some T. b. gambiense
strains do not express the LiTat1.3 VSG gene and, therefore,
patients infected with these strains do not generate detectable
antibodies [22]. For the same reason, the CATT test cannot detect
T. b. rhodesiense infections [23].
There are challenges to developing improved diagnostic assays
and devices for HAT. Due to the very low parasite levels in
patients infected with T. b. gambiense, a test that detects host
antibodies (rather than parasite antigens) is considered more likely
to have the necessary sensitivity. The WHO recommends that
point of care tests (POCT) should follow the ‘ASSURED’ criteria;
which states that a POCT device should be affordable, sensitive,
specific, user-friendly, rapid, equipment-free and deliverable to the
people at need. Lateral flow tests (LFTs) are inexpensive and
simple devices that can rapidly detect nanogram amounts of
antibodies in finger-prick blood samples without the need for any
ancillary equipment [24]. A first-generation LFT for T. b. gambiense
infections, that uses two different purified native VSG antigen
bands (LiTat1.3 and LiTat1.5) to detect anti-VSG antibodies, has
recently entered clinical use as CATT replacement [25]. We have
also produced a promising prototype LFT using a recombinant
invariant surface glycoprotein (rISG65) antigen [26]. In this paper,
we identify another soluble form VSG (sVSG117 also known as
sVSG MITat1.4) with excellent diagnostic properties that we have
used together with rISG65 to create a prototype dual-antigen LFT
that detects T. b. gambiense infections and, to some extent, T. b.
rhodesiense infections.
Materials and Methods
Ethics statement
The serum samples used in this study were from the WHO
HAT Specimen Biobank, archived at the Pasteur Institute, Paris.
Patients were recruited by WHO to provide serum samples as
described in [27] for the development of new diagnostic tests for
HAT and patient consent was collected by WHO at the time of
sample collection. Further local ethical approval for this study was
granted by the Tayside Ethics Review Board. Rodents were used
to propagate T. brucei parasites for the purification of soluble form
variant surface glycoproteins (sVSGs). The animal procedures
were carried out according the United Kingdom Animals
(Scientific Procedures) Act 1986 and according to specific
protocols approved by The University of Dundee Ethics Com-
mittee and as defined and approved in the UK Home Office
Project License PPL 60/3836 held by Michael A.J. Ferguson.
Patient sera
All patients were tested with the CATT test (which was followed
by parasitological analysis) and examined for clinical symptoms of
HAT [27]. Serum samples were stored in the WHO HAT
Specimen Biobank at 280uC and shipped to Dundee on dry
ice where they were thawed, divided into aliquots and stored at
220uC.
sVSG preparations
Bloodstream form T. b. brucei Lister strain 427 clones expressing
four different VSG variants (117, 118, 121 and 221) were
cultivated in rodents as described in [28] and sVSGs were purified
by a simplified version of the method of Cross [28], as described in
[29]. The sVSGs were further purified by gel-filtration using a
Sephacryl-S200 column (4690 cm) equilibrated and eluted with
0.1 M NH4HCO3. The gel-filtration purified sVSGs were
lyophilised to remove NH4HCO3 and stored as dry powders at
4uC before use. Samples were run on an SDS-PAGE gel to check
for purity and were considered .95% pure (data not shown).
Enzyme-linked immunosorbent assays (ELISA)
The ELISA plate preparation details and protocols were as
described in [26]. ELISAs were carried out on both pooled and
individual serum samples. The pooled sera were from stage 1 T. b.
gambiense patients (n = 10), stage 2 T. b. gambiense patients (n = 40)
and matched uninfected patient sera (n = 50). Pooled sera were
diluted 1:1000 in in phosphate buffered saline containing 0.1% w/
v bovine serum albumin (PBS/BSA) and plated in triplicate in
serial (doubling) dilutions in PBS/BSA to 1:32000. Individual sera
were diluted to 1:1000 in PBS/BSA and applied to ELISA plates
in triplicate.
Randomisation and coding of sera
For the sVSG117 single antigen lateral flow test pilot study,
forty T. b. gambiense infection sera and forty matched uninfected
control sera were randomised and coded by a member of the
University of Dundee Tissue Bank. For the dual-antigen lateral
flow test virtual field trial, 431 serum samples, representing a
mixture of T. b. gambiense (n = 150) and T. b. rhodesiense (n = 56)
infection sera and matched uninfected control sera (n = 150 for T.
b. gambiense and n=75 for T. b. rhodesiense) were randomised and
coded by the WHO HAT specimen Biobank.
Author Summary
Human African Trypanosomiasis (HAT) is caused by
infection with Trypanosoma brucei gambiense or T. b.
rhodesiense. The diagnosis of T. b. gambiense infections
currently relies primarily on a Card Agglutination Test for
Trypanosomiasis (CATT), which has acknowledged limita-
tions, and there is no simple test for T. b. rhodesiense
infection. Our overall aim is to produce a simple lateral
flow test device with a similar or better sensitivity and
specificity than CATT but with better stability and ease of
use at point of care. In this study, we identified a particular
variant surface glycoprotein, sVSG117, with good diagnos-
tic potential and combined it with a previously identified
recombinant diagnostic antigen, rISG65, to produce a
prototype dual-antigen lateral flow test. We performed a
virtual field trial by testing the device blind with 431
randomized serum samples provided by the WHO HAT
Specimen Biobank. The results show that, although the
prototype lateral flow test is un-optimized, it was able to
diagnose T. b. gambiense HAT with a sensitivity and
specificity of 97.3% and 83.3% and T. b. rhodesiense HAT
with a sensitivity and specificity of 83.9% and 85.3%.
A Diagnostic Test for Human African Trypanosomiasis
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Lateral flow test prototype production and use
We supplied BBI Solutions with 5 mg sVSG117 to make single
antigen sVSG117 LFT prototype devices for preliminary studies
and with a further 7 mg of sVSG117 and 7 mg of rISG65 [26] to
make dual-antigen LFT prototypes. BBI Solutions is an inmmu-
noassay development and manufacturing company that has
completed more than 250 lateral flow projects over the last 25
years, with manufacturing sites in Europe, USA and South Africa.
Both serum- and blood-accepting pad devices were made. For
LFTs without blood pads, aliquots of 5 ml of patient sera diluted
with 15 ml of PBS were added to the LFTs followed by an 80 ml of
chase-buffer (PBS containing 0.05% Tween 20). For LFTs with
blood pads, aliquots of 5 ml of patient serum were mixed with 5 ml
PBS and 10 ml of freshly reconstituted human type-O blood
erythrocytes. These mixtures were added to the LFTs, followed by
80 ml of chase-buffer (PBS containing 0.05% Tween 20). Tests
were discarded if upper control line was not clearly visible. After
30 min, scoring of the test bands was performed by visual
comparison of freshly completed tests with a scoring card. For the
virtual field trial, two people scored all of the LFT devices
independently. If there was disagreement about the infection-
status of a given serum sample, a third individual provided
adjudication.
Statistics
Line graphs were generated by Microsoft Excel. Receiver
Operator Characteristic (ROC) curves, antigen scatter plots and
tables of sensitivity and specificity scores were generated by
SigmaPlot 12.
Results
Identification of sVSG117 as a potential diagnostic
antigen
Our original rationale for testing HAT sera against a panel of
different sVSGs was to look for the presence of anti-Cross
Reacting Determinant (CRD) IgG antibodies. The CRD is a
peptide-independent epitope common to all sVSGs that is created
upon the cleavage of VSG glycosylphosphatidylinositol (GPI)
membrane anchors by GPI-specific phospholipase C (GPI-PLC)
during cell lysis [30]. However, the ELISA data showed that while
there was anti-peptide and/or anti-CRD IgG antibody titre to all
four sVSGs, the immunoreactivity of both stage 1 and stage 2 T. b.
gambiense HAT patient sera to sVSG117 was far higher than to the
other three (Figure 1). From this result, we decided to pursue
sVSG117 as a potential diagnostic antigen in its own right. We
therefore proceeded to screen randomised and coded sera from 40
Figure 1. Soluble form VSG ELISA results with pooled human T. b. gambiense infection and control sera. Sera were pooled from 1st (blue
lines) and 2nd (red lines) stage T. b. gambiense infected HAT patients and from non-infected patients (green lines) and titrated against ELISA plates
coated with sVSG variants 117 (panel A), 118 (panel B), 121 (Panel C) and 221 (Panel D). Results are expressed as means 6 1 standard deviation of
triplicate measurements. The y-axis is Relative Luminescence Units (RLU).
doi:10.1371/journal.pntd.0002976.g001
A Diagnostic Test for Human African Trypanosomiasis
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T. b. gambiense infected patients and 40 matched uninfected control
patients against sVSG117 coated ELISA plates (Figure 2A). These
data strongly suggested that immunoreactivity to sVSG117 might
be used to reliably discriminate infection from control sera.
Consequently, sVSG117 was developed into an un-optimised
single-antigen prototype lateral flow test (Figure 3A), which was
used with the same set of 80 randomised and coded serum
samples. The visual test scores of the decoded data are shown in
(Figure 2B). The bands were also assessed by quantitative laser
densitometry, as described in [26], (Figure 2C) which showed an
excellent correlation between visual- and densitometer-based
scoring, with an r2 correlation value of 0.957. These data enabled
us to set a cut-off threshold of $1 visual units for discriminating
infected from uninfected sera on this LFT device. Using this
threshold, the test appeared to have 100% sensitivity and 100%
sensitivity, albeit based on a relatively small sample set.
Preliminary evaluation of a dual-antigen lateral flow test
prototype
An un-optimised dual-antigen lateral flow test prototype,
containing one band of recombinant antigen rISG65-1, previously
described in [26], and one band of the native sVSG117 antigen,
described here, was manufactured by BBI Solutions (Figure 3B).
The dual-antigen LFTs were manufactured using the same
antigen coupling conditions as the individual rISG65 [26] and
sVSG117 (this study) single-antigen LFTs. Thus, visual score cut-
offs of $2 for the rISG65 band [26] and of $1 visual units for the
sVSG117 band were expected to define positive immunoreactivity
to each antigen, respectively. However, to establish visual cut off
values directly for this new LFT, the same 80 randomised serum
samples described above were tested blind with the dual-antigen
LFT and scored. After decoding, cut-offs were confirmed as being
$2 and $1 for the rISG65 and sVSG117 test lines, respectively.
Using these values, and the criterion of two positive test lines to
define an infection, the device gave 100% sensitivity and 97.5%
specificity in this pilot study with a limited number of serum
samples (n = 80).
Virtual field trial of the dual antigen lateral flow test
A virtual field study was performed to assess the diagnostic
potential of the dual-antigen LFT. First, aliquots of 431
randomized and coded serum samples, provided by the WHO
HAT Specimen Biobank, were mixed with an aliquot of human
type-O erythrocytes, provided by the Tayside blood-bank, to
produce pseudo blood samples containing red blood cells as well as
serum antibodies. These samples were added to the LFTs fitted
with blood pads, followed by chase buffer, and read independently
by two individuals after 30 min. The LFT was deemed to be
positive if the rISG65 band and sVSG117 had mean visual scores
of $2 and $1, respectively. After decoding by colleagues at the
WHO HAT Specimen Biobank, we were able to plot ROC curves
(Figure 4) and separately assess the sensitivity and specificity of the
LFT to detect T. b. gambiense and T. b. rhodesiense infections using
the following criteria: (i) two positive antigen bands = infection, (ii)
a positive sVSG117 band= infection, (iii) a positive rISG65
band= infection and (iv) any one positive antigen band= infection.
The results, in terms of sensitivity, specificity and the respective
95% confidence intervals (CI) are summarised in (Table 1).
Discussion
Although we selected sVSG117 as a potential diagnostic antigen
from empirical data in this study, our results are also consistent
with population genetics studies that show that the gene encoding
this VSG variant (the same as VSG AnTat 1.8) is ubiquitous in T.
b. gambiense isolates [31,32], whereas those for VSGs 121 and 221
are not [33].
In the virtual field trial, using two positive antigen bands as the
criterion for infection, the sVSG117 and rISG65 dual-antigen
lateral flow test prototype showed a sensitivity of 97.3% (95% CI:
93.3 to 99.2) and a specificity of 83.3% (95% CI: 76.4 to 88.9) for
the detection of T. b. gambiense infections. The sensitivity is
comparable to those reported (87–100%) for the currently
deployed CATT test and for the latex agglutination test which
uses diluted blood and latex beads coated with three different VSG
variants (LiTat1.3, 1.5 and 1.6) [17], but is poorer with respect to
specificity, which have been reported as 85–97% for CATT and
96–99% for the latex test [13–17]. Nevertheless, the dual-antigen
LFT described here is only a prototype that needs to undergo
extensive optimization with respect to antigen-gold coupling,
antigen loading of the test lines and composition of the chase
Figure 2. Scatter plots of the immunoreactivities of infection
and control sera to sVSG117. In each plot, data from infection (left)
and matched uninfected control (right) sera are plotted against (A)
ELISA results, (B) single-antigen LFT results using visual scoring and (C)
single-antigen LFT results using Camag laser densitometry scoring.
doi:10.1371/journal.pntd.0002976.g002
A Diagnostic Test for Human African Trypanosomiasis
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buffer. We therefore suggest that one or both of the sVSG117 and
rISG65 antigens be seriously considered for use in the next
generation of clinical LFT devices for the diagnosis of T. b.
gambiense HAT.
We note that for our prototype dual-antigen LFT the specificity
performance of each individual antigen is relatively poor for
detecting T. b. gambiense infections (Table 1). For example, the
rISG65 test line shows a sensitivity of 98.0% (95% CI: 94.3 to
99.6) but a specificity of only 65.3% (95% CI: 57.1 to 72.9). We
have previously reported the sensitivity and specificity perfor-
mance of a visually-read single-antigen LFT using rISG65 as 88%
(95% CI: 73 to 96) and 93% (95% CI: 80 to 98), respectively [26].
While there is good overlap between the 95% confidence intervals
for these two assessments with respect to sensitivity, we note that
there is a discrepancy with respect to specificity. However, the
previous assessment [26] only used 80 randomized infection and
Figure 3. Single- and dual-antigen prototype LFTs. Photographs of (A) a single-antigen (sVSG117) prototype LFT developed with T. b.
gambiense infection serum and (B) a dual-antigen prototype LFT developed with T. b. gambiense infection serum (left) and control uninfected serum
(right). The positions of the ‘test complete’ control lines and antigen test lines are as indicated. The band intensities are scored visually by comparison
with a test card (C).
doi:10.1371/journal.pntd.0002976.g003
Figure 4. Receiver Operating Characteristics (ROC) graphs of LFT performance. Following independent decoding of the T. b. gambiense (A)
and T. b. rhodesiense (B) patient serum samples, the data were plotted as cumulative sensitivity (true positive rate) versus specificity (false positive
rate). The greater the area under the ROC curve, the greater the accuracy of the test. The curves in black are for ‘both bands positive = infected’; the
curves in red are for ‘sVSG117 band positive = infected’; the curves in green are for ‘srISG65 band positive = infected’ and the curves in yellow are for
‘any band positive = infected’.
doi:10.1371/journal.pntd.0002976.g004
A Diagnostic Test for Human African Trypanosomiasis
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control serum samples and we suggest that the figures reported in
(Table 1) are likely to be more accurate given the significantly
greater sample size (and wider geographic sampling) used in the
virtual field trial. Another possibility is that some of the ‘false-
positive’ results, which drive down the specificity figures for the
dual-antigen LFT, might be due to asymptomatic true positives
that had been missed by the CATT test in the virtual field trial
cohort. As previously noted, this is entirely possible as not all T. b.
gambiense strains express the LiTat1.3 VSG upon which the CATT
test is based [22].
The dual-antigen LFT did not perform as well for detecting T.
b. rhodesiense infections using two positive antigen bands as the
criterion for infection, with a sensitivity of only 58.9% (95% CI:
44.9 to 71.9) and specificity of 97.3% (95% CI: 90.7 to 99.7). A
potentially confounding issue for T. b. rhodesiense immunodiag-
nosis is the typically acute nature of these infections compared to
typically chronic T. b gambiense infections, with the latter more
likely to produce robust antibody responses to parasite antigens.
However, using any one (or both) positive antigen band(s) as the
criterion for T. b. rhodesiense infection improved the sensitivity to
83.9% (95% CI: 71.7 to 92.4) with a specificity of 85.3% (95%
CI: 75.3 to 92.4). As of yet there have been no confirmed cases of
co-existing T. b. rhodesiense and T. b. gambiense infections [34], and
given the current lack of immunodiagnostics for T. b. rhodesiense
infections [35], an optimized version of the dual-band LFT using
the relaxed criteria of one or two positive band(s) to diagnose
HAT might be clinically useful in T. b rhodesiense endemic
regions.
Taken together, the results described in this paper encourage
further development of the dual-antigen LFT device described
here (or one or both of its antigens, i.e., recombinant rISG65-1 and
native sVSG117) for clinical use for the detection of T b. gambiense
infections and, possibly, for T. b rhodesiense infections. LFT
technology offers advantages over CATT with respect to the
‘‘affordable, user-friendly, rapid, equipment-free and deliverable
to the people at need’’ components of the WHO ‘ASSURED’
criteria of ‘‘affordable, sensitive, specific, user-friendly, rapid,
equipment-free and deliverable to the people at need’’. However,
the ‘‘sensitive’’ and ‘‘specific’’ components of the criteria are
clearly also key to success and, while data on the currently
deployed first-generation LFT [25] (that uses native sVSGs
LiTat1.3 and LiTata1.5) are yet to be published, the FIND web
site suggests that its performance is comparable to CATT. Like the
CATT test, and the currently deployed LFT [25], our dual-
antigen LFT requires the cultivation of parasites to make the
native sVSG117 component, although sVSG117 can at least be
prepared from non-human infectious T. b. brucei. Nevertheless, the
ideal second-generation LFT is likely to use two recombinant,
rather than native, antigens and recombinant ISG65 [26] and/or
VSG domains could be the answer.
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